Roche Drug Approved in the U.S. for Rare Autoimmune Disease
By Adria Calatayud
Roche Holding said its Gazyva drug received U.S. Food and Drug Administration approval for the treatment of primary membranous nephropathy, a rare, chronic autoimmune disease that can lead to kidney failure.
The Swiss drugmaker said Monday that this made Gazyva the first medicine specifically authorized for the disease. It also marks the third FDA approval for the medicine in immune-mediated kidney diseases, following previous authorizations in idiopathic nephrotic syndrome and lupus nephritis.
The approval was based on results of a late-stage clinical trial that showed 36% of adults achieved complete remission of proteinuria--or high urine protein levels, a key indicator of kidney damage--at two years, Roche said.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
November 16, 2026 01:32 ET (06:32 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular

5 Stocks to Buy After Earnings

7 Undervalued Stocks That Crushed Earnings

This Newly Undervalued Stock Has Plenty of Growth Ahead

Are These Riskier Bond ETFs Worth the Higher Yields?

